High-Sensitivity Troponin T and Soluble Form of AXL as Long-Term Prognostic Biomarkers after Heart Transplantation

Abstract EN

Antecedents.

Cardiac allograft vasculopathy (CAV) is a frequent complication limiting the long-term (>1 year) survival after heart transplantation (HTx).

CAV is initiated by endothelial dysfunction and can lead to severe cardiovascular (CV) complications.

Since CAV is often clinically silent, biomarkers could help identifying HTx patients at risk of CAV and their severe complications.

Aim.

Evaluate the clinical yield of high-sensitivity cardiac troponin T (hs-cTnT), marker of cardiomyocyte damage, and the soluble form of AXL (sAXL), biomarker of endothelial dysfunction, to assess the prognosis of long-term cardiovascular (CV) events occurring after HTx.

Methods.

96 patients were evaluated at least > 1 year after HTx.

CAV was evaluated by coronary angiography or multisliced tomography, and hs-cTnT and sAXL measured 6 months before or after CAV evaluation.

Patients were followed during 42 ± 15 months for a combined end point including cardiac death, angina or acute myocardial infarction, left ventricular ejection fraction < 50%, or heart failure not due to an acute rejection.

Results.

51 patients (53%) presented CAV at evaluation; 21 of them had CV events.

Hs-cTnT (56 ± 45 versus 20 ± 18 ng/L; p=0.04) and sAXL concentrations (98 ± 51 versus 26 ± 26 ng/L; p=0.01) were significantly higher in patients with CV events.

Hs-cTnT (HR 1.03; 95% CI 1.015–1.042, p=0.0001) and sAXL (HR 1.01; 95% CI 1.001–1.019, p=0.02) were independent predictors of CV events.

A hs-cTnT concentration < 21 ng/L, detected by AUC ROC, predicted the absence of CV events with a predictive value of 91%; sAXL did not add more predictive value to hs-cTnT.

Survival free of CV events was 92% in patients with hs-cTnT < 21 ng/L and 57% in those with hs-cTnT > 21 ng/L (p<0.001).

Conclusion.

Hs-cTnT, but not sAXL, measured during the long-term follow-up of HTx patients appears as a helpful biomarker to identify patients at low risk of adverse CV outcomes.